Products

High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0

China High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0, Find details about China Sofosbuvir, 1190307-88-0 from High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0

Model NO.
Sofosbuvir
CAS
1190307-88-0
Mf
C22h29fn3o9p
Einecs
695-717-4
Appearance
White Powder
Shelf Life
2 Years
Storage
Cool Dry Place
Deliver Time
7-10days
Trademark
Biocar
Transport Package
Bag or Drum
Specification
1kg/Bag; 25kg/Drum
Origin
Wuhan China
HS Code
2942000000
Model NO.
Sofosbuvir
CAS
1190307-88-0
Mf
C22h29fn3o9p
Einecs
695-717-4
Appearance
White Powder
Shelf Life
2 Years
Storage
Cool Dry Place
Deliver Time
7-10days
Trademark
Biocar
Transport Package
Bag or Drum
Specification
1kg/Bag; 25kg/Drum
Origin
Wuhan China
HS Code
2942000000
High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0

High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0
Basic Information
Product Name
1190307-88-0
Appearance
White powder
Assay
99%min 
Test
HPLC 
Certificate
ISO 9001
CAS
1190307-88-0
MF
C22H29FN3O9P
Storage Temperature
Cool Dry Place
High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0Description

Sofosbuvir is first without joint interferon can be safe and effective drug for the treatment of certain types of hepatitis c.Clinical trials confirm for type 1 and 4 c, the drug combination of polyethylene glycol (peg) interferon and ribavirin overall sustained virological response (SVR) is as high as 90%;In view of the type 2 c, the drug plus ribavirin SVR is 89% - 95%;In view of the 3 c, the drug plus ribavirin SVR is 61% - 63%.

Sofosbuvir is drug used in combination with other drugs to treat hepatitis C (HCV). The other drugs used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus genotype and whether the person has cirrhosis.
 High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0


Function

Sofosbuvir is a kind of hepatitis c virus (HCV) NS5B polymerase inhibitors nucleotide analogues, applicable to as united antiviral treatment composition in the treatment of chronic hepatitis c (CHC) infection.
Sofosbuvir confirmed by test can effectively treat genotype 1, 2, 3, or 4 c subjects, including within milan criteria are awaiting liver transplantation of HCC subjects and co-infection of HCV/HIV - 1 subjects.


COA
Batch No.HF150920Quantity850gs
Mfg. DateSep. 20, 2015PackageAs required
Rep. DateSep. 24, 2015Exp. DateSep. 19, 2017
ItemsStandardsResults
AppearanceWhite to off-white solid powderComplies
IdentificationBy IRComplies
By HPLCComplies
Solubility(1% H2O)Colorless to faint yellowComplies
Water Content≤8.0%5.8%
Related SubstanceAny Unknown Individual Impurity: ≤1.50%Complies
Total Impurities: ≤3.00%2.5%
Assay
(HPLC basis on drying)		97.0%~101.5%97.5%
Reference StandardIn-house Standard
ConclusionThe product complied to In-house standard.
StoragePreserve in tight,light-resistant containers in a cool place
 
High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0High Purity Anti HCV 99% Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0

You Might Also Like